ASCO Lung Cancer 2022 – John Varlotto
John Varlotto summarizes which insights have been obtained based on recent studies regarding immunotherapy plus chemoradiation in patients with unresectable or locally advanced stage III non-small cell lung cancer, explains the different effect observed with pemrolizumab and nivolumab and how these results compare to existing data. He discusses if we can extend pathologic complete response rates as well as neoadjuvant chemoimmunotherapy to the unresectable setting and if individualization of therapy confere benefits in this setting.